Researchers have designed potent peptide fusion inhibitors that can neutralize a broad range of influenza viruses and could present a promising avenue for future therapeutics.
Browsing: Basic > Drug Development
Editor, Martha Powell, discusses the issues around the current guidance for treating HAT and gives an overview of the current clinical pipeline being spearheaded by the Drugs for Neglected Diseases initiative.
In this exclusive piece, the authors look at antihelmintics in both animal and human health – arguing that evolution of resistance necessitates drug development.
Novel drug, AQ-13, has demonstrated promise against uncomplicated malaria in a Phase II non-inferiority trial, presenting a potential new tool for tackling drug-resistant strains.
This study from Future Virology, aims to provide insight into the binding features of the ATPase and ssRNA sites of the NS3 helicase.
Virtual screening (VS) is powerful tool in discovering molecular inhibitors that are most likely to bind to drug targets of interest. Here, the authors introduce a novel VS approach, so-called ‘tailored-pharmacophore’, in order to explore inhibitors that overcome drug resistance.
In this report we look at the burden of cryptococcal meningitis, issues with current treatment regimens and future research directions.
Resistance to Naphthoquine has been found in mouse models and might emerge in future as widely used. In this article, the in vivo antimalarial activity of novel naphthoquine derivatives is assessed revealing promising antimalarial candidates for further research.
In this piece, Fabio Gsaller discusses the mechanisms underpinning antifungal resistance in A. fumigatus and his work on the use of 5-flucytosine as a therapeutic agent in managing aspergillosis.